ArticleCancer reports (Hoboken, N.J.)2026

Second-Line Therapy Following Osimertinib in Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer at an Academic Medical Center.

Michael Rafizadeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.